Pacific released a research report on April 24 stating that Baicheng Pharmaceutical (301096.SZ) was given a purchase rating. The main reasons for the rating include: 1) the annual growth rate of clinical and CDMO, and the 23Q4 performance achieved rapid growth; 2) the results of self-research and transformation continued to be displayed, and R&D investment continued to increase; 3) the high growth in new signatures and ongoing orders, and strong certainty about future performance. (Mainichi Keizai Shimbun)
太平洋4月24日发布研报称，给予百诚医药（301096.SZ）买入评级。评级理由主要包括：1）临床及CDMO全年增速靓丽，23Q4业绩实现快速增长；2）自研转化成果不断展现，研发投入持续加大；3）新签及在手订单高增长，未来业绩确定性强。（每日经济新闻）
Pacific released a research report on April 24 stating that Baicheng Pharmaceutical (301096.SZ) was given a purchase rating. The main reasons for the rating include: 1) the annual growth rate of clinical and CDMO, and the 23Q4 performance achieved rapid g
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.